NCT03258554 · OUTCOME

Change in EQ 5D 5L Visual Analogue Scale at One Year

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin · Source last updated 2026-08-27

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Baseline and 1 year

What was measured

The EQ 5D 5L Visual Analogue Scale measures self rated overall health on a vertical visual analogue scale. Possible scores range from 0 for the worst imaginable health state) to 100 for the best imaginable health state. Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: The EQ 5D 5L Visual Analogue Scale measures self rated overall health on a vertical visual analogue scale. Possible scores range from 0 for the worst imaginable health state) to 100 for the best imaginable health state. Change is defined as the time point score minus the baseline score, where positive values indicate improvement and negative values indicate decline.
reporting Status: NOT_POSTED
time Frame: Baseline and 1 year
title: Change in EQ 5D 5L Visual Analogue Scale at One Year
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice